脊椎定位放射線手術を受けている転移性硬膜外脊髄圧迫の高リスク患者に対するリスク適応型脊髄/尾拘束緩和
To learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) in patients with MESCC.
調査の概要
詳細な説明
Primary Objectives The primary protocol objectives are to establish the safety of CDE-SSRS alone in participants with MESCC. Specifically, we aim to maintain an RM risk no greater than 1%. RM will be defined as non-functional paresis per the McCormick score (i.e., Grade D).
Secondary Objectives Secondary objectives include pain control as measured by the Brief Pain Inventory, quality of life as measured by the EQ-5D, symptom burden as measured by the MDASI-SP, overall survival, toxicity, ambulatory rate and cost-effectiveness. LC will be defined radiographically with serial MRI scans by the study radiologist per SPINO criteria.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Amol Ghia, MD
- 電話番号:(832) 628-7357
- メール:ajghia@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
コンタクト:
- Amol Ghia, MD
- 電話番号:832-628-7357
- メール:ajghia@mdanderson.org
-
主任研究者:
- Amol Ghia, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Greater than or equal to 18 years old
- Radiographically documented spinal metastasis on spine MRI within 4 weeks of registration
- Proximity of spinal metastasis to spinal cord or cauda equina which precludes achieving a GTV Dmin of at least 14 Gy per the PI
- All participants must be able to receive single fraction SSRS at the site of interest with 0.01 cc of the spinal cord receiving 14-16 Gy and/or 0.01 cc of the cauda equina receiving 18-20 Gy. The goal of treatment is to select the minimal dose to the organ at risk which will achieve a GTV Dmin of 14 Gy at the treating physician's discretion.
- Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session
- All participants must be able to receive a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gy
- All participants must have a vertebral level site of interest from C1 to S2
- Signed informed consent
- Diagnosis of cancer excluding ultra-radiosensitive histologies (see 4.2)
- Motor strength ≥ 4 out of 5 in extremity or extremities affected by the level of cord compression
- ECOG ≤ 2
Exclusion Criteria:
- Participants with ultra-radiosensitive histologies (lymphoma, multiple myeloma/plasmacytoma)
- Prior history of radiation at the spinal site of interest
- Inability to lie supine comfortably for ≥ 60 minutes
- Progressive neurological deficits due to compression
- Inability of obtain an MRI
- Inability or refusal to undergo an MR simulation
- No eligible for single fraction SSRS for any reason
- Participants who are pregnant
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Stereotactic Radiosurgery
A non-invasive, non-surgical procedure that precisely delivers radiation to cancer on the spine while avoiding surrounding, healthy tissue. |
Given by RTx
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and adverse events (AEs)
時間枠:Through study completion; an average of 1 year.
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Through study completion; an average of 1 year.
|
協力者と研究者
協力者
捜査官
- 主任研究者:Amol Ghia, MD、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。